Pharmacokinetics of Atazanavir in Special Populations
- Conditions
- HIV/AIDSTuberculosis
- Interventions
- Registration Number
- NCT03923231
- Lead Sponsor
- University of Liverpool
- Brief Summary
The lack of data relating to the DDI between ATV and RIF is a major limitation to the use of ATV in patients who require treatment for TB. The VirTUAL Workpackage 2 will explore the necessary dose escalation required to overcome this interaction in non-pregnant HIV-infected adults who are virologically suppressed on bPI-based ART, and who are administered RIF as a study drug, not as part of a full TB treatment regimen. As the specific objective of WP2 is to define the dose of ATV, participants taking an alternative bPI will be transitioned to ATV for the duration of that study. However, to extrapolate the results of this study to special populations such as pregnant and postpartum women, children and adolescents and those with other 'special' characteristics such as obesity (BMI \>30 Kg/m2) or malnutrition (BMI \<18.5 Kg/m2) we propose to undertake sparse sampling for pharmacokinetic analysis from individuals who require ATV-based ART for their clinical care.
Sparse PK data will be obtained opportunistically from participants in the 'special populations' defined above who are receiving ATV as part of their routine clinical care. Subjects will be identified from clinics including the Joint Clinical Research Center (JCRC) and Infectious Diseases Institute (IDI), Kampala, and from sites including Groote Schuur Hospital and Gugulethu Community Health Centre, Cape Town. The ATV/r data from "special populations" will enable validation and refinement of both the PBPK model (WP1) and the pop-PK models (WP4) of the VirTUAL consortium.
- Detailed Description
Overview of VirTUAL Consortium Through the VirTUAL Consortium, the investigators aim to define the optimal use of second-line ART regimens in vulnerable populations with TB co-infection. The primary objective is to 'to determine the optimal dose of boosted atazanavir (ATV/r) when used in combination with RIF-based TB treatment in children, adolescents and pregnant or breastfeeding women.'
The results from this protocol (VirTUAL WP5) will be considered in the context of the full research programme. This can be summarised as follows:
Physiologically-based pharmacokinetic (PBPK) modelling will be developed to understand bPI and RIF Drug-Drug Interactions (DDIs), identifying potential dosing strategies to overcome these in adults and special populations (WP1). This data will inform clinical pharmacokinetic studies exploring the necessary dose escalation of ATV/r, including in the context of high-dose RIF, performed in Kampala (WP2). Intracellular pharmacokinetics will further characterise the DDI (WP3). PBPK and population pharmacokinetics (pop-PK) modelling will be integrated enabling extrapolation to special populations (WP4), and sparse data collection from such populations receiving different combinations of second-line ART and/or TB treatment in Kampala and Cape Town will validate and refine these models (WP5). Capacity building focussing on equipping African scientists with the tools to efficiently define drug dosing in complex populations (WP6), communication and stakeholder engagement (WP7) will increase the application of this methodology to other priority research into pharmacokinetics in special populations.
This protocol describes the sparse pharmacokinetic sampling component which forms Workpackage 5 (WP5) of this research programme. The dose-escalation study (WP2) is an interventional trial which will be conducted in 28 healthy, virologically suppressed volunteers who are on ATV-based second-line ART, are aged over 18, have a normal BMI and are not pregnant or breastfeeding, and which will take place at JCRC, Kampala, Uganda. This study is anticipated to commence in mid-2019, and will explore in detail the changes in pharmacokinetics of ATV/r in both plasma and within cells which take place when rifampicin is co-administered, and will evaluate the necessary dose adjustment which is required to concurrently administer ATV/r with rifampicin-based TB treatment. WP2 will generate intensive data on these 28 well characterized individuals who do not have 'special' characteristics. However, there is a paucity of data on ATV/r disposition in patients who are typically excluded from clinical trials, and therefore the observational data from WP5 will be collected from individuals who fall into the listed categories of special populations and who are being treated with ATV/r for their own health. Data from either WP2 or WP5 alone will be amenable to pharmacometric analysis and bring value, but the combined modelling approach using both sets of data in a combined model will allow the most comprehensive evaluation of ATV/r disposition in the wider population, and will enable projections of dosing recommendations for the special populations who require concurrent treatment for TB whilst receiving ATV/r-based ART.
Individuals will be identified at routine clinic appointments. They (or their guardians) will be asked to keep a detailed record of dosing times for three to five days prior to their study appointment at which sampling will be performed. If they take their medication in the morning, they will be asked to bring the medication to clinic for observation of dosing.
Repeat sampling at subsequent appointments will enable assessment of both between and within-individual variability, for example during periods of rapid childhood growth or during pregnancy and transition back to non-pregnant physiological state.
It is aimed to obtain 20 sparse PK profiles in each of the following groups (pregnant, child \<5, child 6-11, adolescent 12-18, obese (BMI \>30 Kg/m2), malnourished (BMI \<18.5 Kg/m2)), with each individual contributing 4 samples per PK visit, and possibly followed up longitudinally during the study (each individual may attend for a maximum of three study visits). Therefore there will be between 7 (6 participants being sampled on 3 occasions and a final participant sampled on 2 occasions) and 20 (if each participant was only sampled on a single occasion) individual participants per group to generate the 20 sampling 'occasions', with a total number of participants across the six groups included in the study of between 42 and 120.
This will provide an essential clinical dataset to inform the pop-PK modelling approach and validate the PBPK simulations, describing exposure and pharmacokinetic variability in the populations of interest. The data from this work package will be pooled with the data from the study in volunteers and jointly analysed using PK modelling. Differences in the PK parameters for each of the groups will be investigated.
There exist no peer-reviewed published data regarding the transfer of ATV/r into breast milk. Therefore, among women who are enrolled during pregnancy and followed into the postpartum phase, paired breast milk samples will be obtained at the same time as plasma samples.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
-
Evidence of a personally signed and dated informed consent document indicating that the participant (or a legal representative) has been informed of all pertinent aspects of the study.
-
In a child aged ≥7 years (South Africa) or aged ≥8 years (Uganda), evidence of assent to participate
-
Participants who are willing and able to comply with scheduled visits, laboratory tests, and other study procedures.
-
HIV-infected, receiving ATV-based ART treatment OR HIV-infected receiving second-line ART with concurrent rifamycin-based TB treatment
-
Participant is within one of the target populations:
- Pregnant (>20 weeks)
- Body mass index >30 or <18.5 Kg/m2
- Child or adolescent aged <18 years
- Medical, psychiatric or obstetric condition that might affect participation in the stuy based on investigator judgement
- Dissent from a minor
- For pregnant women in Uganda, where the husband is reasonably involved, paternal objection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Adolescents 12-17 Atazanavir 300mg/ Ritonavir 100 mg once daily Adolescents aged 12-17 years who are receiving atazanavir as part of clinical care Pregnant women Atazanavir 300mg/ Ritonavir 100 mg once daily Women who are at least 20 weeks gestation, who are receiving atazanavir as part of clinical care Children <5 years Atazanavir 250 mg / ritonavir 80 mg Children under the age of 5 years who are receiving atazanavir as part of clinical care BMI < 18.5 Atazanavir 300mg/ Ritonavir 100 mg once daily Adults with a BMI of \<18.5 kg/m2 who are receiving atazanavir as part of clinical care BMI >30 Atazanavir 300mg/ Ritonavir 100 mg once daily Adults with a BMI of \>30 kg/m2 who are receiving atazanavir as part of clinical care Children 6-11 Atazanavir 250 mg / ritonavir 80 mg Children aged 6-11 years who are receiving atazanavir as part of clinical care
- Primary Outcome Measures
Name Time Method Atazanavir Cmax 3 years To describe the maximum concentration of atazanavir reached after dosing in the different groups
Atazanavir Ctau 3 years To describe the trough concentration of atazanavir after dosing in the different study groups
Atazanavir AUC0-24 3 years To describe the area under the concentration-time curve from 0 to 24 hours after dosing in the different groups
- Secondary Outcome Measures
Name Time Method Comparison of geometric mean of atazanavir Cmax with healthy adult population 3 years To compare atazanavir Cmax with typical healthy individuals treated with atazanavir who enter a dose escalation study of ATV/r + RIF as WP2 of the VirTUAL programme
Comparison of geometric mean of atazanavir AUC0-24 with healthy adult population 3 years To compare atazanavir AUC0-24 with that of typical healthy adults treated with atazanavir-based ART who enter a dose escalation study of ATV/r + RIF as WP2 of the VirTUAL programme
Comparison of geometric mean of atazanavir Ctau with healthy adult population 3 years To compare atazanavir Ctau with that of typical healthy adults treated with atazanavir-based ART who enter a dose escalation study of ATV/r + RIF as WP2 of the VirTUAL programme
Trial Locations
- Locations (4)
Infectious Diseases Institute
🇺🇬Kampala, Uganda
Joint Clinical Research Centre
🇺🇬Kampala, Uganda
Desmond Tutu HIV Foundation
🇿🇦Cape Town, Western Cape, South Africa
University of Cape Town
🇿🇦Cape Town, Western Cape, South Africa